



TWIST Session 1: Epidemiology and Options for Reducing Drug-Related Infectious Diseases

Tuesday 24th October, 8:30h – 10:00h (Room 5C)

This TWIST Session is open to all Lisbon Addictions Conference participants



Mike Catchpole, *Chief Scientist, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.*

Mike Catchpole is a medical doctor with over 20 years' experience of management of communicable disease surveillance and response at the national and international level. Prior to his appointment as Chief Scientist at ECDC, he was Director of Public Health England's national Centre for Infectious Disease Surveillance and Control. His primary research interests have included HIV and other sexually transmitted infections, the wider health effects of major incidents, and public health information systems development. He has also been a member of the steering groups for a number of European projects, and chaired the Steering Committee of the European Programme for Intervention Epidemiology Training (EPIET) from 2001 to 2006. He has academic appointments, as a visiting

professor, at Imperial College London and City University London.

Session Description:

Learning objective(s):

- Develop an understanding of the epidemiology and determinants of incidence of drug-related infectious diseases
- Develop an understanding of the major approaches to the prevention and control of drug-related infectious diseases, including the evidence on effectiveness and the EU policy context

Scope/main topics covered:

- An overview of the health consequences and the clinical treatment options for the main drug-related infectious diseases
- An overview of the epidemiology of the main drug-related infectious diseases, with a specific focus on the situation in Europe
- Interventions for the prevention and harm-reduction of drug-related infectious diseases
- The evidence-base for the effectiveness of prevention interventions
- Current policy and monitoring systems in the EU

Training/Learning formats:

- Presentation on diseases, their clinical and epidemiological characteristics, and on prevention strategies
- Small group review of case studies of real drug-related infectious disease incidents, with discussion of how the participants would investigate and control those incidents
- Plenary discussion on policy gaps and research priorities

Learning outcome(s) (what should the trainee be able to do following the session?):

- Describe the clinical characteristics and the (European) epidemiology of the major drug-related infectious diseases
- Interpret and assess the potential biases in epidemiological data on drug-related infectious diseases
- Describe the major intervention strategies for prevention and/or harm reduction in respect of drug-related infectious diseases, and the strength of evidence for their effectiveness

Related LxAddictions 2017 sessions:

PS16 (evidence), PS15 (HCV) & SS18 (HIV), among others